Protalix BioTherapeutics Inc. (DE) (PLX)
PLX trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.75
-1.08% on the day
Market cap
$221.6M
Micro cap
Revenue · 2025
$52.7M
-1.2% on 2024
Net income · 2025
-$6.6M
-12.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | PLX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001006281 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $52.7M |
| Net income | -$6.6M |
| Operating income | -$5.5M |
| Net margin | -12.5% |
| Operating margin | -10.4% |
| Revenue growth | -1.2% |
| Cash | $14.7M |
| Total assets | $82.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-08-22 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-08-12 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 971 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LXEO | Lexeo Therapeutics Inc. | $2.74 | -9.87% | $224.8M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.9083 | -4.80% | $229.7M |
| ALEC | Alector Inc. | $1.87 | -10.10% | $208.8M |
| FATE | Fate Therapeutics Inc. | $2.00 | -6.10% | $239.6M |
| SABS | SAB Biotherapeutics Inc. | $2.68 | -5.30% | $243.8M |
| IKT | Inhibikase Therapeutics Inc. | $1.76 | -4.61% | $245.6M |
| IPSC | Century Therapeutics Inc. | $1.38 | -4.17% | $249.9M |
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier